Viking continues push for VK2735 as best in class in obesity

Viking further builds the case that VK2735 could be a best-in-class GIP/GLP-1 dual agonist with additional Phase II data confirming an attractive safety profile and potential for once-monthly subcutaneous dosing.

The biotech also reported more Phase I data from an oral formulation of VK2735 that showed highly competitive efficacy, but at such a high dose that it may not be commercially viable from a manufacturing perspective...